FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC By Ogkologos - January 24, 2025 567 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR 3rd Grader Writes Note for Teacher Battling Breast Cancer to Read... May 24, 2019 Prescribing Exercise as Cancer Treatment: A Conversation with Dr. Kathryn Schmitz November 12, 2019 Advances in Treating Kidney Cancer and Metastatic Prostate Cancer: Research from... January 25, 2024 Robust and Durable Clinical Activity of Tepotinib in Patients with METex14-Skipping... June 21, 2023 Load more HOT NEWS Waiting for Insurance to Cover Her Mammogram Could Have Cost This... Some Women Avoid Breast Cancer Screening After False-Positive Mammogram Results TRACERx: Using blood tests to track lung cancer Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal...
